Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
31 oct. 2023 09h00 HE
|
Gracell Biotechnologies Inc.
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment...
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
30 oct. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
Gracell Biotechnologies to Report Q3 2023 Business Updates on November 13
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
27 sept. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting 100%...
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
26 sept. 2023 16h00 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
19 sept. 2023 09h21 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
14 sept. 2023 09h15 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
24 août 2023 16h10 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
14 août 2023 07h15 HE
|
Gracell Biotechnologies Inc.
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to...
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
31 juil. 2023 16h02 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
31 juil. 2023 09h00 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company...